摘要
[目的]探讨乳腺癌抗雌激素药物耐药蛋白BCAR1在前列腺癌根治标本中的表达及其临床意义。[方法]应用免疫组化法检测BCAR1在97例前列腺癌根治标本中的表达情况,并分析其在肿瘤组织中的表达与各临床病理因素及预后的相关性。[结果]BCAR1在前列腺高级别上皮内瘤变(HGPIN)和前列腺癌组织中的表达显著高于癌旁前列腺组织(P<0.01)。并且BCAR1在癌组织中高表达与高Gleason评分之间存在显著相关性(χ2=6.987,P=0.008)。但BCAR1的表达与血清PSA水平、肿瘤体积、TNM分期及生物学复发之间均无显著相关性(P>0.05)。[结论 ]BCAR1的表达与前列腺癌的分化程度呈负相关,BCAR1可能在前列腺癌的发生过程中发挥作用。
[Purpose] To investigate the expression of BCAR1 in prostate cancer and its clinicopathological significance. [Methods] The immunohistochemistry was used to detect the expression of BCAR1 in 97 cases of radical prostatectomy,and its relationship with clinicopathological features and biochemical recurrence were analyzed. [Results] BCAR1 expression was significantly higher in prostate carcinomas and HGPIN tissues than that in paracancerous tissues（P〈0.05）.There was significant correlation between BCAR1 expressions and the Gleason score（χ2=6.987,P=0.008）.However,no significant correlations were found between BCAR1 expression and the other clinicopathological factors,including serum PSA,TNM stage,tumor volume and biochemical recurrence（P〉0.05）.[Conclusions] The expression level of BCAR1 is negatively associated with the differentiation of prostate carcinoma. BCAR1 may be participate in the development of prostate carcinoma.
出处
《肿瘤学杂志》
CAS
2016年第2期121-124,共4页
Journal of Chinese Oncology
基金
北京市重点学科基础医学学科建设项目(BMU20110254)
